Commercially available lipid formulations of amphotericin B: Are they bioequivalent and therapeutically equivalent?

Acta Biomedica

Volumn 83, Issue 2, 2012, Pages 154-163

  Cifani, Carlo ^a   Costantino, Sarah ^b   Massi, Maurizio ^a   Berrino, Liberato ^b  

^a UNIVERSITY OF CAMERINO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Abelcet ; AmBisome ; Amphocil ; Amphotericin B; Lipid amphotericin formulations

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLOSPORIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CANDIDEMIA; CHILL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL (TOPIC); CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; FEBRILE NEUTROPENIA; FEVER; FUSARIOSIS; HISTOPLASMOSIS; HUMAN; HYPOXIA; INFUSION RELATED REACTION; LUNG ASPERGILLOSIS; NEPHROTOXICITY; NONHUMAN; SHIVERING; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VISCERAL LEISHMANIASIS; ZYGOMYCOSIS;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; INFUSIONS, INTRAVENOUS; LIPIDS; THERAPEUTIC EQUIVALENCY;

EID: 84874041929     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Ostrosky-Zeichner L, Marr KA, Rex JH. Amphotericin B: time for a new "gold standard". Clin Inf Dis 2003; 37: 415-25.
2. Bellmann R. Efficacy and pharmacokinetics of lipid-based Amphotericin B formulations. Clinical Advances in Hematology and Oncology 2009; 7 (suppl 10): 2-4.
3. Pea F. Caratteristiche farmacocinetiche delle formulazioni lipidiche dell'amfotericina B: quali differenze e quali vantaggi? Nuove Prospettive in Terapia 2005; Anno XV 3.
4. Scaglione F. Evoluzione dei farmaci antimicotici. Elsevier, 2009.
5. Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of ambisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993; 3: 429-450.
6. Lopez-Berestein G, Mehta R, Hopfer R, Mehta K, Hersh EM, Juliano R. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv 1983; 1: 37-42.
7. Guo LSS, Fielding RM, Lasic DD. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulphate discs. Intl J Pharm 1991; 75: 45.
8. de Marie S, Janknegt R, Bakker-Woundenberg IA. Clinical use of liposomal and lipid complexed amphotericin B. J Antimicrob Chemother 1994; 33: 907-16.
9. Proffitt RT, Satorius A, Chiang S.M, Sullivan L, AdlerMoore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991; 28 (Suppl B): 49-61.
10. Mehta J. Do variations in molecular structure affect the clinical efficcay and safety of lipid-based Amphotericin B preparations? Leukemia Research 1997; 21: 183-6.
11. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49 (Suppl 1): 31-6.
12. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 1998; 38: 583-92.
13. Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol 2007; 2: 37-58.
14. Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46: 828-33.
15. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002b; 46: 834-40.
16. Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 1991; 35: 1208-13.
17. Olsen SJ, Swerdel MR, Blue B, Clark JM, Bonner DP. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 1991; 43: 831-5.
18. Olson JA, Adler-Moore JP, Marr KA, Rex JH. Comparative efficacies, toxicities, and tissue concentrations of Amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrobial Agents and Chemotherapy 2006; 50: 2122-31.
19. Taylor R, Williams DM, Craven PC, Graybill JR, Drutz DJ, Magee WE. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis 1982; 125: 610-1.
20. Fielding RM, Singer AW, Wang LH, Babbar S, Guo LS. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 1992; 36: 299-307.
21. Vogelsinger H, Weiler S, Djanani A, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrobiol Chemother 2006; 57: 1153-60.
22. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin in neutropenic mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45: 922-6.
23. Andes D. Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resist Update 2004; 7: 185-94.
24. Barker KS, Rogers PD. Recent insights into the mechanisms of antifungal resistance. Curr Infect Dis Resp 2006; 8: 449-56.
25. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49 (Suppl 1): 21-30.
26. Adler-Moore J, Olson JA, Proffitt RT. Alternative dosing regimens of liposomal amphotericin B (Ambisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 2004; 54: 311-7.
27. Perkins WR, Minchey SR, Boni LT, et al. Amphotericin Bphospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992; 1107: 271-82.
28. Mehta RT, McQueen TJ, Keyhani A, López-Berestein G. Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy 1994; 40: 256-64.
29. Legrand P, Vertut-Doi A, Bolard J. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother 1996; 37: 519-33.
30. Vyas SP, Gupta S. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomedicine 2006; 1: 417-32.
31. Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey GP. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1991; 10: 665-8.
32. Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 1998; 42: 1412-6.
33. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000; 13: 243-8.
34. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
35. Adedoyin A, Swenson CE, Bolcsak L.E, et al. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob Agents Chemother 2000; 44: 2900-2.
36. Linden PK. Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opin Pharmacother 2003; 4: 2099-110.
37. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-15.
38. Linder N, Klinger G, Shalit I. Treatment of candida-emia in premature infants: comparison of three amphotericin B preaparations. J Antimicrob Chemother 2003; 52: 663-7.
39. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11: 1463-71.
40. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22: 315-21.
41. Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr. 19. Opin Infect Dis 2002; 15: 593-8.
42. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005; 21: 508-12.
43. Martino R. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Curr Med Res Opin 2004; 20: 485-504.
44. Goldsmith DR, Perry CM. Amphotericin B lipid complex: in visceral leishmaniasis. Drugs 2004; 64: 1905-11.
45. Wingard JR. Lipid formulations of amphotericins: are you a lamper or a splitter? Clin Infect Dis 2002; 35: 891-5.
46. Lanternier F, Lortholary O. Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect 2008; 14 (Suppl. 4): 71-83.
47. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009; 69: 361-92.
48. Barrett JP, Vardulaki KA, Conlon C, et al. Amphotericin B Systematic Review Study Group: A systematic review of the antifungal effectiveness and tolerability of Amphotericin B formulations. Clin Ther 2003; 25: 1295-320.
49. Ellis D. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother 2003; 49 (Suppl. 1): 7-10.
50. Sterba, J. Safety of Aphotericin B formulations. Clinical Advances in Hematology and Oncology 2009; 7 (suppl. 10): 5-6.
51. Turtinen LW, Bremer LA, Prall DN, Schwartzhoff J, Hartsel SC. Distinct cytokine release profiles from human endothelial and THP-1 macrophage-like cells exposed to different amphotericin B formulations. Immunopharmacol Immunotoxicol 2005; 27: 85-93.
52. Simitsopoulou M, Roilides E, Dotis J. Differential expression of cytokines and chemokines in human monocytes induced by lipid-formulations of amphotericin B. Antimicrob Agents Chemoter 2005; 49: 1397-403.
53. Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31: 1155-63.
54. Ullmann AJ, Sanz MA, Tramarin A, et al. Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators. Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries. Clinical Infectious Diseases 2006; 43: 29-38.
55. Walsh TJ, Goodman JL, Pappas, P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother 2001; 45: 3487-96.
56. Ringdén O, Andström E, Remberger M, Svahn BM, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 1994; 14 (Suppl 5): S10-4.
57. Girois SB, Chapuis F, Decullier, E, Revol BG. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 2005; 24: 119-30.
58. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases 2008; 46: 327-60.
59. EMEA CPMP, july 2001. Note for Guidance on the Investigation of Bioavailability and Bioequivalence.